Welcome to our dedicated page for MSCLD SEC filings (Ticker: MSCLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MSCLD's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MSCLD's regulatory disclosures and financial reporting.
Satellos Bioscience Inc. filed its Annual Report on Form 40-F disclosing incorporated exhibits including an Annual Information Form, audited consolidated financial statements for the years ended December 31, 2025 and 2024, and an MD&A.
The filing names PricewaterhouseCoopers LLP as auditor and states the company is an emerging growth company. Shares outstanding were 15,458,903 Common Shares as of the close of the period covered by the annual report. The filing includes SOX certifications and references disclosure controls and internal control information in the MD&A.
Satellos Bioscience reported a 2025 net loss of $24.9 million, up from $20.6 million in 2024, as it increased investment in its lead Duchenne muscular dystrophy drug, SAT-3247. R&D expenses rose to $18.4 million and G&A to $8.0 million.
The company ended 2025 with $27.7 million in cash, cash equivalents and short-term investments and subsequently raised $57.2 million in an equity offering. Management expects this to fund operations through 2027, supporting two Phase 2 SAT-3247 trials in Duchenne.
Satellos initiated BASECAMP, a global, placebo-controlled pediatric Phase 2 trial, and expanded TRAILHEAD, an adult Phase 2 study, where early functional data showed maintained or improved grip strength over roughly 9–13 months of aggregate treatment. New preclinical data in FSHD suggest potential use of SAT-3247 beyond Duchenne.
Satellos Bioscience Inc. reported interim clinical and biomarker results for its oral drug candidate SAT-3247 in Duchenne muscular dystrophy at the 2026 MDA Clinical & Scientific Conference.
In the ongoing Phase 2 TRAILHEAD study in adults with Duchenne, investigators observed continued improvement in handgrip strength and overall stability of elbow and shoulder strength at Day 56 after re-enrollment, with greater strength gains in participants who started with more muscle mass.
A 28-day Phase 1a/b study (CL-101) showed consistent changes across more than 11,000 serum proteins, including reductions in established Duchenne biomarkers within two weeks of SAT-3247 treatment. Satellos also highlighted development of a regenerative index tool now used in the pediatric BASECAMP trial and preclinical data in a mouse model of facioscapulohumeral muscular dystrophy, where 12-week dosing significantly enhanced muscle strength, suggesting broader potential beyond Duchenne.
Satellos Bioscience Inc. is highlighting progress in its lead drug candidate SAT-3247 through two oral presentations and three posters at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference in Orlando from March 8–11. The talks will cover data from a completed Phase 1a/b study of SAT-3247 in healthy volunteers and adults with Duchenne muscular dystrophy, plus new preclinical data in a mouse model of facioscapulohumeral muscular dystrophy. SAT-3247 is an oral small molecule that targets AAK1, aiming to restore muscle stem cell signaling and promote muscle regeneration as a potential disease-modifying treatment for DMD and other degenerative muscle conditions.
Satellos Bioscience Inc., a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases, will present at several upcoming investor conferences. Management is scheduled to participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference, the TD Cowen 46th Annual Health Care Conference, and the Leerink Partners Global Healthcare Conference, through presentations and investor meetings. Live webcasts of the presentations will be accessible on the company’s website in the Investors section. The company highlights its lead oral small molecule candidate SAT-3247, which targets AAK1 and is being developed as a potential disease-modifying treatment for Duchenne muscular dystrophy, supported by ongoing Phase 2 studies in adult and pediatric participants.
Satellos Bioscience Inc. is organizing a virtual key opinion leader event on February 24, 2026 at 3:30 p.m. ET to discuss its lead drug candidate SAT-3247 for Duchenne muscular dystrophy (DMD). Neuromuscular disease expert Dr. Kevin M. Flanigan will review the unmet need and current DMD treatment landscape alongside company management.
The event will cover SAT-3247’s mechanism as an oral small molecule targeting AAK1 to help restore muscle stem-cell signaling disrupted by loss of dystrophin in DMD. It will highlight results from a completed Phase 1a/b trial in healthy volunteers and adults with DMD and provide updates on ongoing Phase 2 studies, including the adult open-label TRAILHEAD study and the global randomized, placebo-controlled pediatric BASECAMP trial.
Satellos Bioscience Inc. completed a public equity offering of 5,168,019 common shares and pre-funded warrants to purchase 495,049 common shares, raising about US$57.2 million in gross proceeds. The common shares were priced at US$10.10 per share, with pre-funded warrants priced at US$10.09999 each.
The company’s common shares began trading on the Nasdaq Global Market under the symbol “MSLE” and remain listed on the Toronto Stock Exchange as “MSCL.” Satellos plans to use the net proceeds mainly to fund research and development, including advancing its SAT-3247 program and other discovery and pre-clinical initiatives, as well as for working capital and general corporate purposes.
Satellos Bioscience Inc. reported dosing the first participant in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept Phase 2 pediatric study of its oral drug SAT-3247 for Duchenne muscular dystrophy.
The trial plans to enroll 51 ambulatory children with Duchenne aged 7 to 9 years. Primary endpoints focus on safety, tolerability and effects on muscle force, while secondary endpoints assess muscle quality, function and regeneration.
SAT-3247 is described as a first-of-its-kind small molecule that targets AAK1 to help restore muscle stem cell signaling disrupted in Duchenne, and is being developed as a potential disease-modifying, dystrophin-independent treatment initially for Duchenne muscular dystrophy.
Satellos Bioscience Inc. is executing an underwritten equity financing under its cross-border shelf program. The company entered an underwriting agreement covering the sale of 4,455,445 common shares and pre-funded warrants to purchase up to 495,049 common shares, plus an option for underwriters to buy 742,574 additional shares. These securities are issued off a previously cleared Form F-10 and Canadian short-form base shelf prospectus allowing up to $150,000,000 of securities. The pre-funded warrants carry a nominal exercise price of CAD$0.00001 per share. The common shares, including those issuable on warrant exercise, are approved for listing on Nasdaq Global Market and the Toronto Stock Exchange, subject to customary conditions.